Bendazac Lysine Inhibition of Human Lens Epithelial Cell Adhesion to Polymethylmethacrylate Intraocular Lenses

Abstract

The aim of the present work was to evaluate the effect of bendazac lysine on the human lens epithelial cell line HLE-B3 adhesion to polymethylmethacrylate (PMMA) intraocular lenses (IOLs). After adherence to IOLs, cells were incubated in the presence of the drug for 24 h. The number of cells contained in a 6-mm² area was then counted with an inverted phase microscope and adherent cells were distinguished from detached floating cells by focusing through the medium. Results obtained show that bendazac is able to induce a linear dose-dependent inhibition of HLE-B3 adhesiveness to PMMA IOLs. In particular, treatment with bendazac 33, 100 and 300 µM resulted in a 15, 32 and 54% inhibition, respectively. Statistical analysis shows that this effect is significant at 100 µM (p < 0.05) and 300 µM (p < 0.01). The analysis of the effects of bendazac on the viability and on the proliferative capacity of HLE-B3 cells did not show any drug-related toxicity up to the concentration of 400 µM. The present study demonstrates that bendazac lysine is able to inhibit adhesion of lens epithelial cells to PMMA IOLs and suggests the potential beneficial use of this drug in preventing secondary cataract development.

Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies

“…80 Despite its antiinflammatory, antinecrotic, anticholinergic, and antilipidemic properties, most research revolves around investigating and demonstrating the agent's primary role in inhibiting protein denaturation. 81 Benzedamine (37), available as the hydrochloride salt, is a locally acting NSAID with local anesthetic and analgesic properties. 82 It has a variety of physicochemical properties and pharmacological activities different from traditional aspirin-like NSAIDs, but which are beneficial to the mechanism of action of benzydamine (37) as an effective topical NSAID with local anesthetic and analgesic effects.…”

Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies

“…80 Despite its antiinflammatory, antinecrotic, anticholinergic, and antilipidemic properties, most research revolves around investigating and demonstrating the agent's primary role in inhibiting protein denaturation. 81 Benzedamine (37), available as the hydrochloride salt, is a locally acting NSAID with local anesthetic and analgesic properties. 82 It has a variety of physicochemical properties and pharmacological activities different from traditional aspirin-like NSAIDs, but which are beneficial to the mechanism of action of benzydamine (37) as an effective topical NSAID with local anesthetic and analgesic effects.…”

Medical treatment of cataract

“…Bendazac's main metabolite, 5‐hydroxybendazac, was found to be an effective hydroxy radical scavenger 52 . Most recently, bendazac was shown to inhibit adhesion of lens epithelial cells to PMMA intraocular lenses in vitro which suggested that bendazac might have potential benefit in preventing secondary cataract development 53 …”

Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies

“…80 Despite its antiinflammatory, antinecrotic, anticholinergic, and antilipidemic properties, most research revolves around investigating and demonstrating the agent's primary role in inhibiting protein denaturation. 81 Benzedamine (37), available as the hydrochloride salt, is a locally acting NSAID with local anesthetic and analgesic properties. 82 It has a variety of physicochemical properties and pharmacological activities different from traditional aspirin-like NSAIDs, but which are beneficial to the mechanism of action of benzydamine (37) as an effective topical NSAID with local anesthetic and analgesic effects.…”

Medical treatment of cataract

“…Bendazac's main metabolite, 5‐hydroxybendazac, was found to be an effective hydroxy radical scavenger 52 . Most recently, bendazac was shown to inhibit adhesion of lens epithelial cells to PMMA intraocular lenses in vitro which suggested that bendazac might have potential benefit in preventing secondary cataract development 53 …”

Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies

“…80 Despite its antiinflammatory, antinecrotic, anticholinergic, and antilipidemic properties, most research revolves around investigating and demonstrating the agent's primary role in inhibiting protein denaturation. 81 Benzedamine (37), available as the hydrochloride salt, is a locally acting NSAID with local anesthetic and analgesic properties. 82 It has a variety of physicochemical properties and pharmacological activities different from traditional aspirin-like NSAIDs, but which are beneficial to the mechanism of action of benzydamine (37) as an effective topical NSAID with local anesthetic and analgesic effects.…”

Medical treatment of cataract

“…Bendazac's main metabolite, 5‐hydroxybendazac, was found to be an effective hydroxy radical scavenger 52 . Most recently, bendazac was shown to inhibit adhesion of lens epithelial cells to PMMA intraocular lenses in vitro which suggested that bendazac might have potential benefit in preventing secondary cataract development 53 …”